Stocks Health care TSHA
NASDAQ · Health careTaysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. brought in $5.5M of revenue over the twelve months to June 30, 2026, down 32.3% from a year earlier. It posted a net loss of $149.6M. In fiscal 2025 capital spending exceeded operating cash flow by $93.8M. At June 30, 2026 it held $455.4M in cash against $49.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Taysha Gene Therapies, Inc. does
Taysha Gene Therapies, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TSHA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9.8M | -$109M | -$0.34 | -$93.8M |
| 2024 | $8.3M | -$89.3M | -$0.36 | -$81.6M |
| 2023 | $15.5M | -$111.6M | -$0.96 | -$76.9M |
| 2022 | $2.5M | -$166M | -$3.78 | -$109M |
| 2021 | n/a | -$174.5M | -$4.64 | -$132.3M |
| 2020 | n/a | -$60M | -$3.40 | -$30.8M |
Latest SEC filings
What Taysha Gene Therapies, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- June 25, 2026
- June 25, 2026
- June 24, 2026
- June 22, 2026
- June 2, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Questions about TSHA
What does Taysha Gene Therapies, Inc. do?
Taysha Gene Therapies, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TSHA.
Is Taysha Gene Therapies, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $149.6M on revenue of $5.5M.
How much revenue does Taysha Gene Therapies, Inc. make?
Over the twelve months to June 30, 2026 Taysha Gene Therapies, Inc. reported revenue of $5.5M. That is 32.3% less than a year earlier.
When did Taysha Gene Therapies, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.
Similar companies
Follow TSHA
Get an email when Taysha Gene Therapies, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TSHA: get an email when it filesWhere the numbers come from
Financial figures are the values Taysha Gene Therapies, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.